Comparative Safety of In Utero Exposure to Buprenorphine Combined With Naloxone Versus Buprenorphine Alone
( JAMA . 2024;332(10):805–816. doi: 10.1001/jama.2024.11501) The incidence of opioid use disorder (OUD) has been rising across the United States over the past few decades, including among pregnant women. Recent data indicate that 8.2 per 1000 pregnant women are affected, with rates reaching 14.6 per 1000 in those with public insurance. Current guidelines recommend treating OUD during pregnancy with buprenorphine or methadone to improve maternal and fetal outcomes. Buprenorphine is available in 2 formulations: with or without naloxone. However, few studies have examined the safety of buprenorphine combined with naloxone during pregnancy. This study aimed to evaluate the risks of adverse outcomes associated with prenatal exposure to buprenorphine and naloxone compared with buprenorphine alone.
Authors
- Kathryn J. Gray (ORCID: https://orcid.org/0000-0002-3541-3724)
- Sonia Hernández–Dı́az (ORCID: https://orcid.org/0000-0003-1458-7642)
- B. Lester (ORCID: https://orcid.org/0000-0002-6151-0288)
- Loreen Straub (ORCID: https://orcid.org/0000-0003-2623-2726)
- Mishka Terplan (ORCID: https://orcid.org/0000-0002-2489-2942)
- Krista F. Huybrechts (ORCID: https://orcid.org/0000-0001-5805-8430)
- E Hülsz Suárez
- Hilary S. Connery (ORCID: https://orcid.org/0000-0002-6169-3731)
- Brian T. Bateman (ORCID: https://orcid.org/0000-0001-5950-8683)
- Seanna Vine (ORCID: https://orcid.org/0000-0002-6908-4201)
- Heidi Zakoul (ORCID: https://orcid.org/0009-0008-3022-9013)
- Helen Mogun
- Yunxia Zhu (ORCID: https://orcid.org/0000-0002-1047-7035)
- H.M. Jones
- JM Davis
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
Publication Details
- Journal
- Obstetric Anesthesia Digest
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1097/01.aoa.0001113044.18351.d5
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00